GLP-1 Eligibility: Clinical Criteria & Biomarker Context

Last reviewed: June 1, 2026

Last updated: June 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Most GLP-1 weight loss medications are prescribed for individuals with a BMI of 30 or higher, or 27 or higher with weight-related health conditions such as type 2 diabetes, hypertension, or sleep apnea. However, medical eligibility extends beyond weight alone—metabolic health, medication history, and individual response patterns matter significantly.

Understanding whether you qualify for GLP-1 therapy requires more than checking a BMI threshold. PlexusDx emphasizes precision wellness: recognizing that genetic and biomarker factors can provide important context for how your body may respond to these medications and whether they align with your health profile.

Standard Medical Eligibility Criteria for GLP-1 Medications

The FDA-approved branded GLP-1 medications (semaglutide, tirzepatide) carry eligibility criteria established through clinical trials. A BMI of 30 kg/m² or higher qualifies most adults; those with a BMI of 27–29.9 kg/m² may qualify if they have at least one weight-related condition such as hypertension, type 2 diabetes, heart disease, or obstructive sleep apnea.

Age, kidney function, thyroid history, and current medications all factor into provider assessment. Individuals with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia type 2 (MEN2) are typically not candidates. Your healthcare provider evaluates the complete clinical picture, not just BMI.

Metabolic and Biomarker Factors That Inform Personalization

Beyond standard criteria, metabolic biomarkers—including fasting glucose, insulin levels, HbA1c, triglycerides, and inflammatory markers—reveal how your body processes nutrients and responds to insulin. These help providers understand your baseline metabolic state and predict which therapeutic approach may be most effective for your individual physiology.

Biomarker Category	Clinical Significance for GLP-1 Eligibility
Fasting Glucose & HbA1c	High levels indicate insulin resistance or prediabetes; GLP-1 medications address both weight and glucose control
Triglycerides & Lipid Profile	Elevated levels suggest metabolic dysfunction; GLP-1s often improve lipid profiles alongside weight loss
Inflammatory Markers (CRP, IL-6)	Chronic inflammation links to insulin resistance and cardiovascular risk; GLP-1 medications have anti-inflammatory effects
Kidney Function (eGFR & Creatinine)	Critical for dosing safety; severe renal impairment may require dose adjustment or contraindicate certain GLP-1 formulations

Genetic Predispositions in GLP-1 and Metabolic Pathways

Genetic variations influence how your body produces and responds to hormones like GLP-1 and leptin, as well as how your metabolism operates. Key variants in the GLP1R, GIPR, FTO, and MC4R genes affect appetite signaling, energy expenditure, and weight regulation at a molecular level.

Understanding these predispositions may help contextualize your individual response pattern and inform a more targeted conversation with your provider about whether GLP-1 therapy aligns with your genetics and metabolic profile. A genetic assessment cannot predict exact medication response, but it can provide valuable clinical context.

Safety Considerations and When GLP-1 Therapy May Not Be Appropriate

Certain medical histories contraindicate GLP-1 use: personal or family history of medullary thyroid carcinoma, MEN2 syndrome, severe renal disease, uncontrolled hypertension, recent GI surgery, or severe diabetic retinopathy. Pregnancy is a contraindication; individuals planning pregnancy should discuss timing with their provider before initiating therapy.

GLP-1 medications slow gastric emptying, which can trigger nausea, vomiting, or constipation—particularly in those with existing GI motility issues or pancreatitis history. Providers assess gallbladder health, pancreatic function, and medication interactions. Honest disclosure of your full medical and medication history is essential for safe, appropriate use.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test reveals predispositions in key GLP-1 pathway genes (GLP1R rs6923761, GIPR rs1800437) and metabolic regulators (FTO rs9939609, MC4R rs17782313). This genetic context may help provide additional insight into your baseline appetite regulation and energy metabolism, supporting a more informed eligibility discussion with your provider.

The genetic test does not predict your exact medication response or guarantee outcomes—rather, it identifies predispositions in peptide and metabolic pathways that can inform personalized conversations. When paired with clinical biomarkers (glucose, lipids, kidney function), this data helps your provider build a more complete picture of your metabolic profile.

Combining genetic insights with standard medical evaluation can support a more confident, individualized treatment decision. If you qualify based on BMI and health status, understanding your genetic and biomarker context strengthens the case for why GLP-1 therapy may be a good fit for your specific physiology and goals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $229-$309/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.